BCDA
$1.28
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
Intraday
Recent News
Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off
The recent price decline of 46% in BioCardia, Inc.'s ( NASDAQ:BCDA ) stock may have disappointed insiders who bought...
BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ...
BioCardia Inc (BCDA) advances regulatory discussions and trials, despite increased expenses and a net loss in Q1 2025.
First subject enrolled in BioCardia’s Phase III heart failure therapy trial
The enrolment procedure took place at BayCare Morton Plant Hospital in the US.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 6,307% surge in interest CG Oncology (CGON), 3,377% surge in interest Chemomab Therapeutics (CMMB), 3,029% surge in interest BioCardia (BCDA), 1,244% surge in interest Senti Biosciences (SNTI), 1,175% surge in interest Tevogen Bio Holdings (TVGN), 332% surge in interest Regulus Therapeutics (RGLS), 223% surge in interest Spr
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure
BioCardia aims to advance the study by enrolling 39 subjects across the US.